NeoGenomics, Inc.: NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR MRD Test in HR+ HER2- Breast Cancer

FT. MYERS, FL / ACCESSWIRE / June 21, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today confirms

Related Keywords

Fort Myers ,Florida ,United States ,Georgia ,Tampa ,North Carolina ,United Kingdom ,Texas ,Research Triangle Park ,Atlanta ,China ,California ,Tennessee ,Singapore ,Houston ,Aliso Viejo ,Cambridge ,Cambridgeshire ,Switzerland ,Chicago ,Illinois ,Charlie Eidson ,Marla Lipsyc Sharf ,Karen Chandler Smith ,Cancer Research United Kingdom Cambridge Institute ,Neogenomics Inc ,Inivata Limited ,Company Pharma Services Division ,Nasdaq ,Company Annual Report On Form ,University Of Cambridge ,Astrazeneca ,Corporate Development ,Dana Farber Cancer Institute ,Consilium Strategic Communications ,Clinical Oncology ,Annual Meeting ,Chief Medical Officer ,Clinical Oncology Fellow ,Pharma Services Division ,Privacy Practices ,Neogenomics Laboratories ,Breakthrough Device Designation ,Annual Report ,Investor Relations ,Media Contacts ,Neogenomics ,Liquid ,Biopsy ,Ubsidiary ,Inivata ,Nnounces ,Data ,Emonstrating ,Linical ,Potential ,Radar ,Pest ,Ther2 ,Breast ,Dancer ,